New drug combo shows early potential for treating ...
MIT researchers developed a new immunotherapy strategy combining three drugs to boost the immune system against pancreatic cancer, showing promise in eliminating tumors in mice. The therapy targets the CD155/TIGIT axis, alongside PD-1 inhibition and CD40 agonist antibodies, leading to significant tumor shrinkage. Clinical trials are expected to begin later this year.
Reference News
New drug combo shows early potential for treating ...
MIT researchers developed a new immunotherapy strategy combining three drugs to boost the immune system against pancreatic cancer, showing promise in eliminating tumors in mice. The therapy targets the CD155/TIGIT axis, alongside PD-1 inhibition and CD40 agonist antibodies, leading to significant tumor shrinkage. Clinical trials are expected to begin later this year.